Moroctocog alfa
| Clinical data | |
|---|---|
| Trade names | ReFacto |
| AHFS/Drugs.com | UK Drug Information |
| Legal status |
|
| Identifiers | |
| ATC code | B02BD02 (WHO) |
| Chemical data | |
| Molecular mass | 170 kDa |
Moroctocog alfa (trade name ReFacto) is a recombinant antihemophilic factor genetically engineered from Chinese hamster ovary (CHO) cell line. Chemically it is a glycoprotein.[1] It is manufactured by Genetics Institute, Inc. and used to control and prevent hemorrhagic bleeding and prophylaxis associated with surgery or to reduce the number of spontaneous bleeding episodes in patients with hemophilia A. It is partially a recombinant coagulation factor VIII since it has an amino acid sequence which compares to the 90 + 80 kDa form of factor VIII (BDDrFVIII).[2] It also has posttranslational modifications which are similar to those of the plasma-derived molecule. It can not prevent hemorrhagic bleeding associated with von Willebrand's disease since it is not a von Willebrand factor.
References
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- Articles with dead external links from February 2014
- Drugs with non-standard legal status
- Infobox drug articles without a structure image
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Recombinant proteins
- Blood and blood forming organ drug stubs
